RicercaInizia una nuova ricerca
NOTA: è possibile cercare una corrispondenza esatta usando i doppi apici, ad es: "evoluzione della specie". Qualora si cerchi un identificativo, è consigliabile cercarlo in due modi differenti: tra apici con caratteri speciali es: "978-94-6366-274" oppure senza caratteri speciali solo come sequenza numerica: es 978946366274.
The French-Italian mitoxantrone-Interferon-beta Trial: a 3-year randomised study
2007-01-01 G. EDAN; G. COMI; C. LEBRUN; D.BRASSAT; C. LUBETZKI; B. STANKOFF; A. TOURBAH; J. PELLETIER; CM. DEBOUVERIE; C. CONFAVREUX; S. BLANC; E. ROULLET; C. TRANCHANT; P.HAUTECOEUR; A. MACKOWIAK; L. MAGY; L.RUMBACH; O. GOUT; D. AFAUVRE; P.CLAVELOU; T. MOREAU; G.L. MANCARDI; M. ZAFFARONI; M.P. AMATO; M. TROIANO; L. DURELLI; D. VEILLARD; E. LE PAGE; M. FILIPPI; S. MORRISSEY
The independent comparison of interferon (incomin) trial: correlation of neutralising antibodies anti-interferon beta with clinical response and mri activity
2003-01-01 P. BARBERO; E. VERDUN; M. CLERICO; A. PIPIERI; A. RICCI; M. BERGUI; E. VERSINO; G. ANTONELLI; M. ZAFFARONI; A. GHEZZI; E. MONTANARI; L. DURELLI
The optims study. I looking for a treatment response marker
2005-01-01 L. DURELLI; E. VERDUN; P. BARBERO; M. CLERICO; B. FERRERO; E. VERSINO; G. GIULIANI; E. MONTANARI; THE OPTIMS STUDY GROUP
The optims trial: the first prospective long term predictivity analysis trial of a treatment response marker to immunomodulatory drug in ms.
2005-01-01 L. DURELLI; P. BARBERO; M. CLERICO; A. RICCI; B. FERRERO; G. CONTESSA; E. VERSINO; G. GIULIANI; E. MONTANARI; AND THE OPTIMS STUDY GROUP; ITALY
The Real Life Impact of Early Versus delayed Treatment of Interferon beta on Long Term Disability Progression i relapsing-Remitting Multiple Sclerosis
2008-01-01 Maria Trojano; Maria Pia Amato; Carlo Avolio; Roberto Bergamaschi; Paola Cavalla; Luca Durelli; Aurora Fuiani; Angelo Ghezzi; Alessandra Lugaresi; Giacomo Lus; Enrico Millefiorini; Damiano Paolicelli; Francesco Patti; Fabio Pellegrini; Carlo Pozzilli; Paolo Rossi; Giuseppe Salemi; Marica Vianello; Paolo Livrea; Giancarlo Comi
To differentiate the indication to treat the clinically isolated syndrome on the bases of different clinical onsets. The subgroup analyses from a Cochrane meta-analysis
2009-01-01 Marinella Clerico; Fabrizio Faggiano; jacqueline Palace; Mar Tintore'; Luca Durelli
To evaluate anti-interferon (ifn) neutralizing antibody (nab) in relapsing remitting (rr) ms patients treated over the long term with an ifn beta-1b dose higher than that currently approved.
2005-01-01 A. RICCI; P. BARBERO; A PIPIERI; B. FERRERO; M. CUCCI; M. CLERICO; G. CONTESSA; L. GIORDANO; L. DURELLI; AND THE OPTIMS STUDY GROUP
To prevent conversion of clinically isolated syndromes to clinically defined multiple sclerosis: a Cochrane Metanalysis
2008-01-01 Marinella Clerico; Fabrizio Faggiano; Jacqueline palace; George Rice; Mar Tintore'; Luca Durelli
Treatment for delaying conversion of the first demyelinating event to Multiple Sclerosis: a cochrane review on use of recombinant interferon beta or glatiramer acetate
2005-01-01 M. CLERICO; F. FAGGIANO; J. PALACE; G. RICE; M. TINTOR; L. DURELLI
Treatment for delaying conversion of the first demyelinating event to Multiple Sclerosis: a cochrane review on use of recombinant interferon beta or glatiramer acetate
2005-01-01 M. CLERICO; G. RICE; M. TINTORE' SUBIRANA; F. FAGGIANO; J. PALACE; L. DURELLI
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| The French-Italian mitoxantrone-Interferon-beta Trial: a 3-year randomised study | 2007 | G. EDAN; G. COMI; C. LEBRUN; D.BRASSAT; C. LUBETZKI; B. STANKOFF; A. TOURBAH; J. PELLETIER; CM. DEBOUVERIE; C. CONFAVREUX; S. BLANC; E. ROULLET; C. TRANCHANT; P.HAUTECOEUR; A. MACKOWIAK; L. MAGY; L.RUMBACH; O. GOUT; D. AFAUVRE; P.CLAVELOU; T. MOREAU; G.L. MANCARDI; M. ZAFFARONI; M.P. AMATO; M. TROIANO; L. DURELLI; D. VEILLARD; E. LE PAGE; M. FILIPPI; S. MORRISSEY | |
| The independent comparison of interferon (incomin) trial: correlation of neutralising antibodies anti-interferon beta with clinical response and mri activity | 2003 | P. BARBERO; E. VERDUN; M. CLERICO; A. PIPIERI; A. RICCI; M. BERGUI; E. VERSINO; G. ANTONELLI; M. ZAFFARONI; A. GHEZZI; E. MONTANARI; L. DURELLI | |
| The optims study. I looking for a treatment response marker | 2005 | L. DURELLI; E. VERDUN; P. BARBERO; M. CLERICO; B. FERRERO; E. VERSINO; G. GIULIANI; E. MONTANARI; THE OPTIMS STUDY GROUP | |
| The optims trial: the first prospective long term predictivity analysis trial of a treatment response marker to immunomodulatory drug in ms. | 2005 | L. DURELLI; P. BARBERO; M. CLERICO; A. RICCI; B. FERRERO; G. CONTESSA; E. VERSINO; G. GIULIANI; E. MONTANARI; AND THE OPTIMS STUDY GROUP; ITALY | |
| The Real Life Impact of Early Versus delayed Treatment of Interferon beta on Long Term Disability Progression i relapsing-Remitting Multiple Sclerosis | 2008 | Maria Trojano; Maria Pia Amato; Carlo Avolio; Roberto Bergamaschi; Paola Cavalla; Luca Durelli; Aurora Fuiani; Angelo Ghezzi; Alessandra Lugaresi; Giacomo Lus; Enrico Millefiorini; Damiano Paolicelli; Francesco Patti; Fabio Pellegrini; Carlo Pozzilli; Paolo Rossi; Giuseppe Salemi; Marica Vianello; Paolo Livrea; Giancarlo Comi | |
| To differentiate the indication to treat the clinically isolated syndrome on the bases of different clinical onsets. The subgroup analyses from a Cochrane meta-analysis | 2009 | Marinella Clerico; Fabrizio Faggiano; jacqueline Palace; Mar Tintore'; Luca Durelli | |
| To evaluate anti-interferon (ifn) neutralizing antibody (nab) in relapsing remitting (rr) ms patients treated over the long term with an ifn beta-1b dose higher than that currently approved. | 2005 | A. RICCI; P. BARBERO; A PIPIERI; B. FERRERO; M. CUCCI; M. CLERICO; G. CONTESSA; L. GIORDANO; L. DURELLI; AND THE OPTIMS STUDY GROUP | |
| To prevent conversion of clinically isolated syndromes to clinically defined multiple sclerosis: a Cochrane Metanalysis | 2008 | Marinella Clerico; Fabrizio Faggiano; Jacqueline palace; George Rice; Mar Tintore'; Luca Durelli | |
| Treatment for delaying conversion of the first demyelinating event to Multiple Sclerosis: a cochrane review on use of recombinant interferon beta or glatiramer acetate | 2005 | M. CLERICO; F. FAGGIANO; J. PALACE; G. RICE; M. TINTOR; L. DURELLI | |
| Treatment for delaying conversion of the first demyelinating event to Multiple Sclerosis: a cochrane review on use of recombinant interferon beta or glatiramer acetate | 2005 | M. CLERICO; G. RICE; M. TINTORE' SUBIRANA; F. FAGGIANO; J. PALACE; L. DURELLI |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Opzioni
Scopri
Tipologia
- 04-CONTRIBUTO IN ATTI DI CONVEGNO 137
- 04-CONTRIBUTO IN ATTI DI CONVEGNO... 137
Data di pubblicazione
- 2010 - 2017 20
- 2002 - 2009 117
Editore
- Springer-Verlag 53
- Lippincot Williams and Wilkins 14
- SAGE publications 9
- SAGE Publications 8
- SAGE Pubblications 6
- Antonio Federico 5
- Lippincott Williams and Wilkins 4
- Robert A. Gross 4
- Springer 4
- Springer Verlag-Italia 4
Rivista
- JOURNAL OF NEUROLOGY 1
Keyword
- Active learning 1
- Cooperative learning 1
- Flipped classroom 1
- Global education 1
- Global university 1
- INTERFERONI 1
- SCLEROSI MULTIPLA 1
- Student centered teaching methods 1
- TH17 1
- TH22 1
Lingua
- eng 137
Accesso al fulltext
- no fulltext 135
- open 2